SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen� Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) It wasn't that long ago that obesity drugs were considered a lifestyle drug. Doctors, the Food and Drug Administration, and insurers believed losing weight was a vanity issue.

An investigation for current long-term investors in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) over potential wrongdoing by certain officers and directors of Orexigen Therapeutics was announced and NASDAQ:OREX stockholders should contact ...

Orexigen Therapeutics, Inc. (NASDAQ:OREX) a biopharmaceutical company that focuses on the development of pharmaceutical product candidates for the treatment of obesity closed down in its previous session (-3.29%) on 789,604 shares traded after ...

Regarding the report "The Long Term Returns of Obesity Prevention Policies" unveiled this week by the Campaign to End Obesity (CEO), Orexigen Therapeutics, Inc. (Nasdaq: OREX) issued the following statement: Orexigen commends CEO as well as the ...

New York, NY -- (SBWIRE) -- 04/23/2013 -- Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Orexigen Therapeutics, Inc. (NASDAQ:OREX), and Astex Pharmaceuticals, Inc.

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Orexigen� Therapeutics, Inc. OREX, a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter ended March 31, 2013.

Orexigen Therapeutics, Inc.(NASDAQ:OREX) shares gained 4.29% to $6.57. The company, on Mar. 13, posted fourth-quarter net loss of $32.5 million or $0.41 per share, wider than $4.3 million or $0.09 per share in the previous year quarter.

NEW YORK, May 13, 2013 (BUSINESS WIRE) -- Levi & Korsinsky, LLP is investigating Orexigen Therapeutics, Inc. (nasdaqgs:OREX), and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.

Regarding the report "The Long Term Returns of Obesity Prevention Policies" unveiled this week by the Campaign to End Obesity (CEO), Orexigen Therapeutics, Inc. (NASDAQ: OREX) issued the following statement. Orexigen commends CEO as well as the ...